Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Daclatasvir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 7/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.68 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.68 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.68 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Daclatasvir SCHEMBL12188233 | 1.00 | CYP3A4 (0.71) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| Daclatasvir SCHEMBL27133901 | 1.00 | CYP3A4 (0.71) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL16282866 | 0.98 | CYP3A4 (0.69) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL17066318 | 0.98 | CYP3A4 (0.69) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL19619824 | 0.98 | CYP3A4 (0.69) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL17066325 | 0.97 | CYP3A4 (0.68) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL17066320 | 0.97 | CYP3A4 (0.67) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL4976901 | 0.96 | CYP3A4 (0.67) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL12168206 | 0.96 | CYP3A4 (0.67) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL16509239 | 0.96 | CYP3A4 (0.67) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025122482-A1 | METHODS AND COMPOSITIONS TO INHIBIT TRIBBLES 2 FOR CANCER THERAPY | HENRY FORD HEALTH SYSTEM (US) | 2025-06-12 | — | — | WO | disclosed |
| US-20240050415-A1 | DACLATASVIR FOR USE IN TREATING LUNG AND PROSTATE CANCER | HENRY FORD HEALTH SYSTEM (US) | 2024-02-15 | — | — | US | disclosed |
| US-20160194352-A1 | AMORPHOUS FORMS OF DACLATASVIR DIHYDROCHLORIDE | REDDYS LAB LTD DR (IN) | 2016-07-07 | — | — | US | disclosed |
| US-20160194352-A1 | AMORPHOUS FORMS OF DACLATASVIR DIHYDROCHLORIDE | REDDYS LAB LTD DR (IN) | 2016-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194352-A1 | AMORPHOUS FORMS OF DACLATASVIR DIHYDROCHLORIDE | SAMHD1, DCTD, TYMP | CYP3A4 37/4885CYP2C9 344/4885NR1I2 3538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.